Oxford Immunotec Reports Third Quarter 2018 Financial Results

  • Closed transformative deal to sell U.S. laboratory services business to Quest Diagnostics
  • T-SPOT®.TB tests sold in the third quarter exceeded one million tests for the first time
  • Significant improvement in GAAP net loss; first quarter of positive non-GAAP adjusted......
    . .
    Veröffentlicht von: Finanzen.at - Nachrichten Ticker - Friday, 9 November
Share |